Quest Launching High-Sensitivity CRP Assay To Assess CVD Risk
This article was originally published in The Gray Sheet
Executive Summary
Quest Diagnostics began introducing Dade Behring's N High Sensitivity C-reactive protein assay to the physician market on Nov. 15. Dade Behring's 510(k) submission, for risk assessment of cardiovascular and peripheral vascular disease, cleared FDA on Oct. 25.